Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Blood-Derived graft may improve dental implant success

NCT ID NCT07584629

Disease control Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two ways to rebuild jawbone for dental implants in 12 patients. One method used a blood-derived graft (LPRF block), the other used a mix of the patient's own bone and cow bone mineral. Over 25 months, researchers measured bone growth and implant survival. The goal was to see which approach works better for creating a strong foundation for implants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LPRF block (a blood-derived graft) and a mixture of autogenous bone with deproteinized bovine bone mineral
What this could lead to
If successful, this could point toward a better, less invasive way to rebuild jawbone for dental implants, potentially improving implant success and reducing complications.
What could go wrong
This is a very small study (12 patients) and only compares two graft types. Results may not apply to everyone, and bone grafting always carries risks like infection or graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Jul 2018

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females, with ASA I or II, between 18 and 80 years old * 2 implant sites requiring vertical bone augmentation prior to implant placement * Both sites in the same jaw * Good general health as documented by self-assessment Exclusion Criteria: * Any systemic medical condition that could interfere with the surgical procedure, planned treatment or healing of the patient * Immunosuppression, Diabetes, Anticoagulation or Antiaggregatory medication. * Current pregnancy or breast feeding/ lactating at the time of recruitment. * Radiotherapy or Chemotherapy in head and neck area. * Intravenous and oral bisphosphonate therapy. * Smoking * Unwillingness to return for the follow-up examination. * Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for surgical procedure or would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unrealistic expectations * Presence of osseous pathologies, that might interfere with normal wound healing * Presence of oral lesions (such as ulceration, malignancy) * Local inflammation, including untreated periodontitis * Patients with inadequate oral hygiene or unmotivated for adequate home care

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar bone resorption are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alveolar bone resorption

Contacts and locations

Locations

  • UZ Leuven

    Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.